Brokers Set Expectations for Medicus Pharma Q1 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Research analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Medicus Pharma in a report released on Tuesday, March 31st. Brookline Capital Markets analyst K. Raja expects that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.10) EPS.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50).

A number of other brokerages have also recently issued reports on MDCX. Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.50.

Medicus Pharma Trading Down 8.5%

Shares of NASDAQ MDCX opened at $0.42 on Wednesday. The stock has a market cap of $10.73 million, a price-to-earnings ratio of -0.15 and a beta of 1.20. Medicus Pharma has a 52 week low of $0.37 and a 52 week high of $8.94. The company’s 50-day moving average price is $0.92 and its 200 day moving average price is $1.67.

Institutional Trading of Medicus Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDCX. Jane Street Group LLC acquired a new position in Medicus Pharma in the 2nd quarter valued at about $41,000. Osaic Holdings Inc. boosted its stake in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares during the last quarter. Brave Asset Management Inc. purchased a new stake in shares of Medicus Pharma during the third quarter worth about $46,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Medicus Pharma during the third quarter worth about $59,000. Finally, Private Advisor Group LLC raised its position in shares of Medicus Pharma by 3.8% in the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.